New technology for treating cardiac arrhythmia introduced in Kazakhstan
The Heart Center UMC team has implemented the latest Farapulse electro-pulse ablation technology for the treatment of patients with cardiac arrhythmia, El.kz cites heartcenter.kz.
The technology is characterized by greater efficiency, safety and less time required for correcting cardiac arrhythmias. It is used when atrial fibrillation appears in patients – a rapid and irregular contraction of the upper chambers of the heart.
The master class was conducted by Professor Serge Boveda, Clinique Pasteur clinic, France. The professor is also the secretary of the European Heart Rhythm Association (EHRA), which unites cardiologists and specialists from all over the world. “This is a minimally invasive procedure, during which a catheter is inserted through the femoral vein and brought to the heart. Next, electroporation, or the effect of electric fields, is applied to tissues to form pores and destroy pathogenic cells. The procedure itself takes no more than an hour. The recovery period takes 1-2 days,” the doctor shared.
The professor's visit began with a lecture and presentation of the technology, and question and answer session. Next, UMC specialists, together with Dr. Boveda, continued with the practical part in the catheterization laboratory.
“Today is a great day for us. Farapulse technology, in addition to cryoablation and radiofrequency ablation, which are used to treat atrial fibrillation, is used all over the world. But in Central Asia and among the CIS countries, it is being introduced for the first time in Kazakhstan, at UMC clinics. The technology allows adjusting the device in such a way that it does not harm nearby tissues and affects only pathological areas. We planned to carry out 8 procedures during the two days of the master class. We hope that the treatment will help improve the quality of life of our patients,” said Omirbek Nuralinov, head of the Department of Interventional Arrhythmology at the Heart Center UMC.
“In the coming decades, cardiovascular diseases will remain the main cause of death. Therefore, the introduction of new technology is very important for our patients with atrial fibrillation. About 1,000 patients with this diagnosis need treatment every year. The methodology is safe, fast and easy to adapt, especially for young professionals. Also, treatment is provided to our citizens free of charge, within the framework of the state quota,” noted Yuriy Pya, Chairman of the Executive Board of the UMC.
UMC specialists have gained advanced experience in the application of this technology and will continue to provide our citizens with high-quality and latest methods of treating cardiovascular diseases.
Subscribe to our Telegram channel and be the first to know the news!